# Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

> **NCT05875961** · PHASE1 · COMPLETED · sponsor: **Seqirus** · enrollment: 600 (actual)

## Conditions studied

- Influenza, Human
- Infections
- Respiratory Tract Infections
- Virus Diseases
- Infection Viral

## Interventions

- **BIOLOGICAL:** Low dose A/H2N3c + standard dose MF59
- **BIOLOGICAL:** Intermediate dose A/H2N3c + standard dose MF59
- **BIOLOGICAL:** High dose A/H2N3c + standard dose MF59
- **BIOLOGICAL:** High dose A/H2N3c non-adjuvanted
- **BIOLOGICAL:** Lowest dose A/H2N3c + high dose MF59
- **BIOLOGICAL:** Low dose A/H2N3c + high dose MF59

## Key facts

- **NCT ID:** NCT05875961
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-15
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875961, "Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05875961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*